Acurx Pharmaceuticals has enrolled the first patient in its Phase 2 PATHFINDER trial testing ibezapolstat for multiply recurrent C. difficile infection (rCDI). This trial will evaluate the drug's safety and efficacy in about 20 patients with at least three CDI episodes in the past year, aiming to support a U.S. New Drug Application based on a single Phase 3 trial. Ibezapolstat is a novel antibiotic designed to treat and prevent CDI recurrence, potentially replacing current two-drug regimens with one. Acurx plans a larger Phase 3 ASPIRE trial pending funding, with FDA and EMA alignment on the clinical program. Successful development could address a major public health issue affecting 500,000 U.S. patients annually with high recurrence and mortality rates.
Acurx Pharmaceuticals' clinical trial news is presented with Pluang's Health sector market data for context. As of Sep 29, 2026 18:14 WIB, 44 of 100 Health-sector US stocks rose while 49 fell. Notable movers include ABCL at USD 14.23 with a 2.23% increase and a typical hold time of 41 days, and GSK at USD 50.74 with a 2.09% rise and a typical hold time of 92 days.
Kraig Biocraft Laboratories has completed its first commercial shipment of recombinant spider silk yarn to a leading global sports brand for use in a high-performance athletic apparel pilot program. This milestone marks the company's transition from ...
MINISO's CFO, Jingjing Zhang, purchased approximately HK$2.7 million worth of company shares on September 29, 2026, adding to a previous acquisition of US$400,000 in 2023. This move signals strong management confidence in MINISO's long-term value and...
iSpecimen is supporting a hospital laboratory by coordinating the collection of over 1,700 human biospecimens, including serum, plasma, cerebrospinal fluid, and urine, to validate a new chemistry analyzer for clinical use. The specimens cover a wide ...
Arlo Technologies introduced the Essential Solar Security Camera, a solar-powered device designed for year-round security with minimal maintenance. It features an integrated solar panel and a powerful 14,790mAh battery that can last up to six months ...
Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG...
